Company intelligence / Profile preview

Optispan

Ownership: Private
Development stage: Commercial

Overview

Optispan provides commercial precision health services focused on early risk detection and personalized interventions to extend healthspan. The company uses advanced diagnostics—including AI-enhanced biometrics—and delivers individualized care plans aimed at preventing chronic illness and optimizing long-term vitality. There are no published clinical trial results or investigational drugs.

Therapeutic areas: OtherMetabolic Disorders
Modalities: DiagnosticsPersonalized interventions (including lifestyle, biomarker-driven plans)
Industry: Non-Academic Healthcare

Drug pipeline

2 assets

rapamycin

Commercial

Indications: Aging, Immune function

1 more asset in the full pipeline.

Request access →

Partnerships

Investment partnership with Ora Biomedical via Optispan Ventures

Beyond the preview

Go deeper on Optispan.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Optispan.

Explore the full profile